You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
C
Not yet recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • With and Without MyD88 and/or CD79B Mutations
  • (no location specified)
2022-04-01
Apr 1, 2022
A
Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
2022-02-22
Feb 22, 2022
S
Recruiting
  • Diffuse Large B-cell Lymphoma
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai JiaoTong University School of Medicine
2021-12-30
Dec 30, 2021
C
Recruiting
  • Diffuse Large B-cell Lymphoma
  • TQ-B3525 tablets
  • Beijing, Beijing, China
  • +1 more
2021-08-17
Aug 17, 2021
S
Not yet recruiting
  • DLBCL
  • Seoul, Korea, Republic of
    Seoul National University Hospital
2022-02-15
Feb 15, 2022
N
Withdrawn
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Tisagenlecleucel
  • (no location specified)
2022-02-25
Feb 25, 2022
U
Active, not recruiting
  • Non Hodgkin Lymphoma
  • R-CHOP + acalabrutinib
  • Southampton, Hampshire, United Kingdom
  • +6 more
2021-08-16
Aug 16, 2021
I
Recruiting
  • Diffuse Large B Cell Lymphoma
  • molecular characterization
  • Meldola, FC, Italy
  • +3 more
2021-02-25
Feb 25, 2021
K
Active, not recruiting
  • Refractory Diffuse Large B Cell Lymphoma
  • KTE-C19
  • +3 more
  • Duarte, California
  • +4 more
2021-11-30
Nov 30, 2021
M
Recruiting
  • DLBCL
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota, Masonic Cancer Center
2021-07-08
Jul 8, 2021
U
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Colchester, Essex, United Kingdom
  • +2 more
2021-10-20
Oct 20, 2021
N
Recruiting
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
R
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Lenalidomide and Rituximab (ZR2)
  • Shanghai, Shanghai, China
    Shanghai Ruijin Hospital
2020-09-09
Sep 9, 2020
I
Terminated
  • Diffuse Large B-Cell Lymphoma
  • Ottawa, Ontario, Canada
  • +1 more
2021-06-16
Jun 16, 2021
N
Completed
  • Diffuse Large B-cell Lymphoma
  • Atlanta, Georgia
  • +4 more
2022-02-18
Feb 18, 2022
O
Recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • Yamagata, Japan
    Yamagata University Hospital
2021-10-22
Oct 22, 2021
C
Recruiting
  • Relapsed Large B-cell Lymphoma
  • +5 more
  • CRC01
  • +2 more
  • Seoul, Korea, Republic of
    Samsung Medical Center
2021-04-29
Apr 29, 2021
A
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Brisbane, Queensland, Australia
  • +2 more
2022-02-14
Feb 14, 2022
W
Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2021-05-03
May 3, 2021
A
Recruiting
  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
  • ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
  • Beijing, Beijing, China
  • +14 more
2021-07-19
Jul 19, 2021
N
Not yet recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +5 more
  • Decitabine and Cedazuridine
  • Nivolumab
  • New York, New York
    Laura and Isaac Perlmutter Cancer Center at NYU Langone
2022-04-05
Apr 5, 2022
N
Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-03-31
Mar 31, 2022